Approximately 40% of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) have a PIK3CA mutation4–8. This evidence concerns the gene ERBB2 and breast cancer.